Who are ALKS 37's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Sevoflurane, Sufentanil, topiramate, propranolol, Remifentanil and/or propofol, Propofol-based total intravenous anesthesia, Stiripentol Oral Capsule, Auris-Sedina.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/alks-37.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

ALKS 37 — Competitive Intelligence Brief

ALKS 37 (ALKS 37) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: GABA_A receptor agonist. Area: Neurology.

phase 2 GABA_A receptor agonist GABA_A receptor Neurology Small molecule Live · refreshed every 30 min

Target snapshot

ALKS 37 (ALKS 37) — Alkermes, Inc.. ALKS 37 is a dual GABA_A receptor agonist.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
ALKS 37 TARGET	ALKS 37	Alkermes, Inc.	phase 2	GABA_A receptor agonist	GABA_A receptor
Sevoflurane, Sufentanil	Sevoflurane, Sufentanil	University of Saskatchewan	phase 3	General anesthetic, Opioid analgesic	GABA_A receptor, Mu-opioid receptor
topiramate, propranolol	topiramate, propranolol	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	phase 3	Anticonvulsant	Voltage-dependent sodium channels, GABA_A receptor
Remifentanil and/or propofol	Remifentanil and/or propofol	Alder Hey Children's NHS Foundation Trust	phase 3	Opioid analgesic, Sedative-hypnotic	Opioid receptors, GABA_A receptor
Propofol-based total intravenous anesthesia	Propofol-based total intravenous anesthesia	The Cleveland Clinic	phase 3	GABA_A receptor agonist	GABA_A receptor
Stiripentol Oral Capsule	Stiripentol Oral Capsule	Biocodex	phase 3	GABA_A receptor modulator	GABA_A receptor
Auris-Sedina	Auris-Sedina	Laboratorios Osorio de Moraes Ltda.	phase 3	Benzodiazepine	GABA_A receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (GABA_A receptor agonist class)

Alkermes, Inc. · 1 drug in this class
Assistance Publique - Hôpitaux de Paris · 1 drug in this class
Centre Hospitalier Universitaire de Saint Etienne · 1 drug in this class
The Cleveland Clinic · 1 drug in this class
University Hospital, Clermont-Ferrand · 1 drug in this class
Xiaobo Yang, MD · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ALKS 37 — Competitive Intelligence Brief. https://druglandscape.com/ci/alks-37. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab